CN120267815A - 用于治疗胰腺炎的方法 - Google Patents

用于治疗胰腺炎的方法 Download PDF

Info

Publication number
CN120267815A
CN120267815A CN202510438979.9A CN202510438979A CN120267815A CN 120267815 A CN120267815 A CN 120267815A CN 202510438979 A CN202510438979 A CN 202510438979A CN 120267815 A CN120267815 A CN 120267815A
Authority
CN
China
Prior art keywords
pancreatitis
antibody
markers
pancreatic
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510438979.9A
Other languages
English (en)
Chinese (zh)
Inventor
D·D·恩格莱
D·A·图维森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cold Spring Harbor Laboratory
Original Assignee
Cold Spring Harbor Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Laboratory filed Critical Cold Spring Harbor Laboratory
Publication of CN120267815A publication Critical patent/CN120267815A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202510438979.9A 2018-09-10 2019-09-09 用于治疗胰腺炎的方法 Pending CN120267815A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862729354P 2018-09-10 2018-09-10
US62/729,354 2018-09-10
PCT/US2019/050262 WO2020055768A1 (en) 2018-09-10 2019-09-09 Methods for treating pancreatitis
CN201980073543.7A CN113056286B (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980073543.7A Division CN113056286B (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法

Publications (1)

Publication Number Publication Date
CN120267815A true CN120267815A (zh) 2025-07-08

Family

ID=69776851

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510438979.9A Pending CN120267815A (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法
CN201980073543.7A Active CN113056286B (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980073543.7A Active CN113056286B (zh) 2018-09-10 2019-09-09 用于治疗胰腺炎的方法

Country Status (13)

Country Link
US (1) US12378320B2 (https=)
EP (1) EP3849605A4 (https=)
JP (1) JP7560445B2 (https=)
KR (1) KR20210073515A (https=)
CN (2) CN120267815A (https=)
AU (1) AU2019337564A1 (https=)
BR (1) BR112021004444A2 (https=)
CA (1) CA3112382A1 (https=)
CL (2) CL2021000585A1 (https=)
IL (1) IL281343A (https=)
MX (1) MX2021002761A (https=)
SG (1) SG11202102416SA (https=)
WO (1) WO2020055768A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002761A (es) 2018-09-10 2021-05-31 Cold Spring Harbor Laboratory Metodos para tratar la pancreatitis.
EP4277932A4 (en) * 2021-01-12 2024-06-12 Yeda Research and Development Co. Ltd Antibodies to cancer glycosylation and uses thereof
CA3214598A1 (en) * 2021-03-26 2022-09-29 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
US20250302409A1 (en) * 2024-03-26 2025-10-02 Hepatiq, Inc. Determining pancreas disease using functional imaging

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4471057A (en) 1981-06-30 1984-09-11 The Wistar Institute Detection of colorectal carcinoma
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
JPS63159763A (ja) * 1986-12-24 1988-07-02 Fujirebio Inc 逆受身凝集反応試薬
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
SI2540309T1 (en) 2005-08-05 2018-04-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and their uses
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
KR20200075044A (ko) 2008-01-22 2020-06-25 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
AU2009279503B2 (en) * 2008-08-08 2014-05-29 Immunomedics, Inc. Anti-pancreatic cancer antibodies
WO2014145016A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CA2918223A1 (en) 2013-07-17 2015-01-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2014332442B2 (en) 2013-08-26 2019-12-19 Biontech Research And Development, Inc. Nucleic acids encoding human antibodies to Sialyl-Lewis
CN104623639A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 白介素22二聚体在制备治疗胰腺炎药物中的应用
PE20170256A1 (es) 2014-01-24 2017-04-22 Ngm Biopharmaceuticals Inc Proteinas de union y sus metodos de uso
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
MX2021002761A (es) 2018-09-10 2021-05-31 Cold Spring Harbor Laboratory Metodos para tratar la pancreatitis.

Also Published As

Publication number Publication date
JP2022500382A (ja) 2022-01-04
US20220049011A1 (en) 2022-02-17
CN113056286A (zh) 2021-06-29
AU2019337564A1 (en) 2021-05-06
CN113056286B (zh) 2025-04-29
IL281343A (en) 2021-04-29
CL2021000585A1 (es) 2021-08-13
JP7560445B2 (ja) 2024-10-02
CL2022000091A1 (es) 2022-11-18
US12378320B2 (en) 2025-08-05
EP3849605A4 (en) 2022-06-15
KR20210073515A (ko) 2021-06-18
BR112021004444A2 (pt) 2021-06-01
CA3112382A1 (en) 2020-03-19
EP3849605A1 (en) 2021-07-21
MX2021002761A (es) 2021-05-31
WO2020055768A1 (en) 2020-03-19
SG11202102416SA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
Rozenfeld et al. Pathogenesis of Fabry nephropathy: the pathways leading to fibrosis
CN113056286B (zh) 用于治疗胰腺炎的方法
EP3360571B1 (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
US20150309033A1 (en) Podxl protein in colorectal cancer
CN110168372A (zh) 用于确定dpp3的方法和治疗方法
CN121248782A (zh) 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
CN109563154B (zh) 抗帕多瓦因子ix抗体
US9790503B2 (en) VHZ for diagnosis and treatment of cancer
CN113508300A (zh) 用于人类阿尔茨海默病的新型生物标记物
JP2017526916A (ja) 癌の診断
KR20180042423A (ko) Cd37 의 검출을 위한 항체 및 검정
US20220125876A1 (en) A method of immune modulation by modulating abcf1
JP2011530283A (ja) がんの診断および治療のためのｖｈｚ
JP2023523145A (ja) リポ蛋白（ａ）に対するイソ型非依存性抗体
US20220289840A1 (en) Antibodies To Cell Adhesion Molecule-Related/Down-Regulated By Oncogenes (CDON) And Uses Thereof
US8334105B2 (en) Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
JP2021531007A (ja) Ｖｉｓｔａに対する受容体
JP2022526131A (ja) 肝細胞癌診断用バイオマーカーセレブロンと、これに特異的な新規なモノクローナル抗体
RU2839356C2 (ru) Способы лечения панкреатита
TW202246354A (zh) 抗烯醇化酶1（eno1）抗體及其應用
US10385340B2 (en) Autoimmune disease treatments
WO2025217258A1 (en) Nptx1 antibodies
Englert A pathophysiologic evaluation of the receptor for advanced glycation end products (RAGE) in the lung
Hinkofer Distinction of vasculitis-associated ANCA subsets and their pathogenic role in a new mouse model with the humanized target antigen
HK1252633B (en) Antibodies binding to an intracellular prl-1 or prl-3 polypeptide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination